Based on these two trials, DESTINY-Lung01 and DESTINY-Lung02, T-DXd 5.4 mg/kg was approved by the FDA and the European Medicines Agency (EMA) for patients with previously treated HER2 -mutant metastatic NSCLC marking the first approval of an ADC for lung cancer
Shel Wellness & Aesthetic Center. Who Can Benefit From Peptide Therapy With BPC-157 BPC-157 is short for Body Protection Compound-157. It is a lab-made peptide derived from a compound found in the gastrointestinal system, and it has been used primarily in clinical practice to support mobility, joint health, tissue healing, and recovery
L.DooE.HoofnagleJ
Over the past five years, REI has modernized the DSIP platform, improving cloud migration and system reliability
Recalls & Warnings June 15, 2003 FTC Alleges "Heartbar" Made Deceptive Claims About Effectiveness On June 12, 2003, the Federal Trade Commission (FTC) announced that Unither Pharma, Inc